



Review

Role of ocular blood flow in normal tension glaucoma

Xingdi Wu^{a,1}, Katarzyna Konieczka^{b,1}, Xin Liu^a, Min Chen^a, Ke Yao^a, Kaijun Wang^{a,**}, Josef Flammer^{b,*}

^a Eye Center of the 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

^b Department of Ophthalmology, University of Basel, Mittlere Strasse 91, Basel, 4031, Switzerland

ARTICLE INFO

Keywords:

Normal tension glaucoma
Ocular blood flow
Vascular dysregulation
Flammer syndrome
Oxidative stress

ABSTRACT

Background: Normal tension glaucoma (NTG) is a multifactorial disease in the pathogenesis of which intraocular pressure (IOP)-independent factors play a key role.

Main text: There is considerable evidence that impairment of the ocular blood flow (OBF) is involved both in the onset and progression of this disease. With the development of the hypothesis of OBF in NTG, various imaging techniques have been developed to evaluate the OBF and blood vessels. Moreover, vascular dysregulation, which is a main factor in Flammer syndrome, was frequently observed in NTG patients. Disturbed OBF leads to increased oxidative stress, which plays an important role in the pathogenesis of glaucomatous optic neuropathy. These results suggested that IOP-independent management may provide alternative treatment options for NTG patients.

Conclusions: In this review, we mainly focus on the mechanisms of the abnormal OBF in NTG.

1. Introduction

Glaucoma is a group of disorders characterized by cupping of the optic nerve head (ONH) and visual field damage.¹ As the leading global cause of irreversible blindness, it is predicted that globally the number of those with glaucoma will increase to 111.8 million by 2040, the majority of whom will be in Asia and Africa.² Glaucoma can be classified as open-angle glaucoma or angle-closure glaucoma according to the morphology of the anterior chamber angle. The common characteristics of all forms of glaucoma are the loss of retinal ganglion cells (RGCs), thinning of the retinal nerve fiber layer (RNFL), and increasing excavation of the optic disc.³ Open-angle glaucoma comprises the majority of cases in the United States and Western Europe, whereas angle-closure glaucoma predominates in China and other Asian countries.⁴ Normal tension glaucoma (NTG), a special subtype of primary open-angle glaucoma (POAG), is a progressive optic neuropathy with an intraocular pressure (IOP) within the normal range.⁵ In the absence of the major risk factor for glaucoma, that is, an elevated IOP, NTG presents a clinical challenge.

NTG is a form of multifactorial optic neuropathy whose etiology remains strongly debated. To date, no single factor has been able to fully explain its pathogenesis. The main factors contributing to NTG-related

glaucomatous optic neuropathy (GON) include vascular factors and ocular blood flow (OBF), the translaminal pressure gradient, and immune and genetic factors.^{6–8} These factors can lead to RGC loss and axonal damage through several pathways. Among the various risk factors besides IOP, vascular factors have been recognized as a significant component in NTG pathogenesis, because many studies have found that the vascular structures of NTG patients are altered or dysregulated.⁶ In 1959, Harrington first noted that impaired blood flow can cause optic nerve vulnerability to glaucomatous damage, even at a statistically normal IOP setting.⁹ Subsequently, various research groups have discussed the vascular theories of glaucoma, particularly in NTG.

The aim of this review is to summarize the current understanding of risk factors for NTG and briefly describe the technologies for clinical measurements of OBF. The role of the vascular factors and OBF in NTG pathogenesis and some of the new treatments will also be discussed.

2. Risk factors for NTG

To identify risk factors for GON, most researchers tend to focus on NTG patients. In NTG, factors other than IOP are likely to have a clearer role in GON. It should be noted that the risk factors for GON in NTG also play a role in high tension glaucoma (HTG), but at a lower frequency. A

* Corresponding author.

** Corresponding author.

E-mail addresses: ze_wkj@zju.edu.cn (K. Wang), josef.flammer@unibas.ch (J. Flammer).

¹ These authors contributed equally to this work.

meta-analysis showed that disc hemorrhage, myopia, sex, aging, and some systemic vascular diseases were prognostic for NTG progression.¹⁰

2.1. Intraocular pressure

Clinical studies have shown that IOP is the main risk factor in the development and progression of both HTG and NTG.^{11,12} Although reducing IOP does not always prevent NTG development, it does slow it in many cases.¹³ With the exception of the IOP level, the IOP fluctuation also appears to be related with the development of NTG. Lee et al. found that IOP fluctuation is related to the structural deterioration in NTG, particularly with progressive thinning of the peripapillary RNFL.¹⁴ However, the relationship between IOP fluctuations and glaucoma progression remains greatly debated.¹⁵

2.2. Ethnic origin

In general, as damage occurs or progresses at a lower IOP, there will be a higher probability of additional risk factors being involved. In Asia, the prevalence of POAG is approximately 2.34%.¹⁶ The proportion of NTG varies for different countries. In previous epidemiological studies in Asia, NTG accounted for the majority (52%–92%) of open-angle glaucoma,¹⁷ while in Western countries, NTG comprises approximately 30% of POAG patients.¹⁸ This variation may be caused by both genetic and environmental components.

2.3. Myopia

In Asians, the high prevalence of high myopia may be partly responsible for the high incidence of NTG.¹⁸ Myopia has been demonstrated to be a risk factor associated with glaucoma progression.^{19,20} However, some other studies indicated that this may not be the case.^{21,22} Lee et al. found that these contradictions were attributable to different study populations. In addition, they suggested that progression of NTG and optic disc changes may observably influence glaucomatous eyes with myopia but have no effect on emmetropia or hyperopia.¹⁴ The underlying mechanism linking NTG and myopia remains unclear. One possible explanation is that an increase in the myopic axial length may increase the sensitivity of myopia to glaucomatous damage.²³

2.4. Age and sex

Age is a statistically important clinical risk factor for the severity of glaucoma in NTG eyes.¹⁷ This could, in theory, indicate that older individuals may display increased vulnerability to glaucomatous damage. NTG occurs more often in women.²⁴ This also fits to the observation that the Flammer Syndrome is more common in females.²⁵

2.5. Disc hemorrhage

It has been reported that disc hemorrhage is an important negative prognostic factor for NTG and may be a marker of progressive damage to the RNFL, leading to deterioration of visual field function.²⁶ Nonetheless, the mechanism underlying the onset of disc hemorrhage has not been fully elucidated. Furlanetto et al. demonstrated that a history of migraine, narrower baseline neuroretinal rim width, systemic β -blockers usage, low mean systolic blood pressure, and low mean arterial ocular perfusion pressure (OPP) are risk factors for disc hemorrhage development in NTG, which emphasizes the importance of IOP-independent factors in the pathogenesis of NTG disc hemorrhage.²⁷ Disc hemorrhages, which are a sign of partial vascular abnormalities, tend to be associated with NTG.²⁸ In addition, Nitta et al. found that the occurrence of disc hemorrhage may contribute to structural deterioration and the reduction of the radial peripapillary capillary vessel density in NTG patients.²⁹ On the one hand, Quigley et al. demonstrated that disc hemorrhage is caused by microvascular disruption during back-bowing of the lamina cribrosa.³⁰ On the

other hand, other reports showed that systemic vascular diseases, including migraine, diabetes, and hypertension, can cause optic disc damage and increase the incidence of disc hemorrhage.^{31,32} With respect to diabetes, previous studies have shown that it may increase the risk for open-angle glaucoma.^{33,34} These observations are supported by the evidence of impaired autoregulation during NTG development.^{35,36} In summary, these results suggest that OBF plays an important role in NTG.

3. Anatomy and clinical measurements of ocular blood flow

3.1. Anatomy of the optic nerve blood supply

The blood supply of the eye primarily arises from the ophthalmic artery, which is a branch of the internal carotid artery. The ONH is the main structure affected in glaucomatous optic atrophy. The superficial nerve fiber layer of the ONH is mainly supplied by the branches from the central retinal artery. The prelaminar region, immediately posterior to the nerve fiber layer, is mainly supplied by branches from the short posterior ciliary arteries and vessels originating from the arterial circle of Zinn-Haller.^{35,37,38} OBF reduction might be a key factor in GON pathogenesis in NTG.³⁹ Previous studies showed that glaucoma patients have a reduced OBF in various ocular tissues, including the retina, choroid, iris, and optic nerve, particularly in cases of NTG.^{35,40} Xu et al. determined and compared the changes in the retinal vasculature in HTG and NTG by optical coherence tomography angiography (OCTA), and found that the density of perfused retinal vessels was significantly more reduced in NTG than in HTG eyes.⁴¹

3.2. Assessment of ocular blood flow

A variety of different methods for measuring OBF have been described in previous research, including laser speckle flowgraphy, color Doppler imaging (CDI), Doppler Fourier domain optical coherence tomography (Doppler FD-OCT), fluorescein angiography, and OCTA among others.³⁷ Although many techniques have advanced in recent years, there remains no gold standard. Each technique measures different aspects of OBF, but each has certain limitations.

3.2.1. Color Doppler imaging

CDI is a widely used method for the analysis of parameters of the retrobulbar vasculature, including blood flow velocities, the pulsatility index, and the resistive index.⁴² Although CDI is an outstanding approach to assess the large arteries, it has limitations in quantifying vessel diameters and calculating total RBF.⁴³ Matthiessen et al. suggested that CDI measurements had a good reproducibility, and proved that CDI appears to be an appropriate method for examining retrobulbar blood flow velocities both in clinical practice and research.⁴⁴ Numerous studies have evaluated ocular hemodynamics by CDI in POAG and NTG patients.^{45,46} These reports confirmed, to some extent, the changes in the retrobulbar flow velocity in glaucoma.

3.2.2. Doppler Fourier domain optical coherence tomography

OCT is a noninvasive technique with high-resolution cross-sectional imaging, and is commonly used in glaucoma evaluation.⁴⁷ Recently, with the development of Doppler FD-OCT, visualization and quantification of blood flow have become possible. OCT can also detect the Doppler shift of reflected light, which provides information regarding flow and movement.⁴⁸ The speed of OCT imaging has been greatly improved due to the development of Fourier domain techniques.⁴⁹ The main advantage of this technique is the ability to rapidly measure the total retinal blood flow.⁵⁰ There are still some limitations of Doppler FD-OCT, including phase wrapping artifact in vessels with high blood flow velocities and measurement errors caused by eye motion. Wang et al. found that the total retinal blood flow significantly decreased in eyes with glaucoma and the deficit in blood flow correlated well with the severity of the visual field loss as shown by Doppler FD-OCT.⁵¹ This new technique can

routinely measure total retinal blood flow in a clinical setting. It will be helpful in diagnosing and treating optic nerve and retinal diseases related to poor blood flow.

3.2.3. Fluorescein angiography

Angiography visualizes the penetration of fluorescent dye through ocular vessels. Fluorescein angiography has traditionally been used to assess the microvascular supply of the prelaminar region of the optic disc and the peripapillary choroid.⁵² It has advantages related to investigating the retinal circulation in more detail as well as the ONH circulation, but has limitations in analyzing choroidal circulation.^{35,42} A number of studies have used fluorescein angiography for the qualitative and quantitative evaluation of angiography, showing the hemodynamic changes in patients with POAG, NTG, or primary angle-closure glaucoma.^{53,54} Plange et al. found that the retinal arteriovenous passage time was prolonged in NTG patients.⁵⁵ In addition, retinal hemodynamics was correlated with OPP and systemic blood pressure (BP), which may reflect impaired autoregulation in NTG.

3.2.4. Optical coherence tomography angiography

OCTA is a relatively newly developed imaging technique that allows the detection of blood flow through the motion contrast generated by erythrocytes. It allows noninvasive visualization of the microcirculation in the ONH, peripapillary retina, and macula.⁵⁶ OCTA can provide quantitative, rapid, and detailed information about the microvasculature, and has thus emerged as a promising method for glaucoma assessment and management.⁵⁷ Liu et al. first reported that a lower peripapillary vessel density were found in glaucomatous eyes compared with normal eyes by OCTA.⁵⁸ Scripsema et al. also found a significant decrease of peripapillary capillary densities in NTG eyes when compared with normal eyes.⁵⁹ It appears that the vascular density decreased with the increase of glaucoma severity. Some differences were found between the NTG and POAG eyes, suggesting that there may be pathophysiological differences with different effects on the area around the ONH and peripapillary. Additional studies are required to elucidate these differences.⁶⁰ Current OCTA studies support its potential in clinical practice for the diagnosis and staging of glaucoma and in evaluating its progression, thereby providing a better understanding of its pathogenic mechanisms.

4. The role of ocular blood flow in NTG

Some studies have shown that an inadequate blood supply can lead to RGC loss.^{61–63} Chronic ischemia and reperfusion damage have been considered to be involved.³⁵ The reduction of OBF is the result of multiple factors. Some experts have focused on OPP, which is an important parameter that determines the perfusion of the ONH.^{64–66} OPP is calculated as arterial BP minus IOP. This calculation was primarily based on animal studies.⁶⁷ It was based on two assumptions: that the ratio of the arterial BP in the eye to the BP at the arm is constant, and that RVP is equal to the IOP. From today's point of view, however, neither of these is quite correct. Although the calculation of PP described above was not optimal, there is a significant correlation between PP and glaucoma progression. Besides, when assessing the risk status of an individual patient, separate consideration of RVP, BP, and IOP is more meaningful and helpful.⁶⁸ As summarized in several reviews, low BP compromises the OPP at the optic disc and thus leads to glaucomatous damage.^{35,36}

Systemic hypotension has been demonstrated to be a clear risk factor for glaucomatous damage.⁶⁹ In the Baltimore Eye Study, after 9 years of follow-up, a cohort study indicated that risk factors for POAG development were lower systolic BP, systolic OPP, diastolic OPP, and mean OPP.⁷⁰ Previous studies have also shown that a low partial pressure (PP), particularly a fluctuating PP, is considered to be a risk factor for GON development.^{66,71} A fluctuating OPP can lead to an unstable OBF and oxygen supply and, therefore, to oxidative stress, which may be of relevance in glaucoma pathogenesis.⁷² Charlson et al. suggested that the duration and magnitude of the nocturnal BP decline, particularly when

10 mmHg lower than the daytime BP, were risk factors for visual field deterioration in NTG patients.⁷³ In a prospective longitudinal study of 65 NTG patients, a low nocturnal diastolic OPP at baseline was proposed to be an important predictive factor for visual field deterioration at 5 years.⁷⁴ A retrospective study aimed to investigate the long-term clinical course of NTG patients.⁷⁵ It was found that a low OPP may exacerbate the progression of visual field loss. The dipping pattern was also associated with glaucomatous visual field deterioration, and a more pronounced dipping was associated with greater visual field deterioration. NTG patients exhibit significantly greater nocturnal BP dips, which may in turn lead to OPP fluctuation with ischemic episodes at the ONH, and were associated with the progressive visual field defect.⁷⁶ Consequently, systemic hypotension, particularly nocturnal BP dips, may play an important role in disease progression in NTG individuals. However, not all patients with a low BP will progress.⁷⁷ Whether or not an impairment occurs as a result of a low BP depends on its autoregulation.

Orgul et al. reported that 65% of NTG patients with systemic hypotension suffered from vasospasms.⁷⁸ This suggests that there is an association between low BP and vasospastic disorders, which may reflect the additional effect of vascular dysregulation. The blood flow is not only determined by the PP, but also local resistance. An increase in vein resistance will increase venous pressure, thereby reducing the PP.⁷⁹ There are complex interactions between OBF and OPP with local flow resistance, and the response to a reduction in OPP is the regulation of resistivity. There is evidence that in patients with low BP, a reduction in OPP reduces OBF owing to autoregulatory changes and defective adaptations.⁴⁰ Ramli et al. found that the nocturnal supine BP parameters and OPP in the NTG group were significantly lower than in normal controls.⁸⁰ Their findings indicated that there may be defective autoregulatory mechanisms in NTG patients. Lindeman et al. revealed that alterations in BP combined with the heart rate suggest impaired BP regulation in glaucoma patients, particularly NTG patients.⁸¹ These results implied that vascular regulation or dysregulation may play an important role in the GON pathogenesis. Barbosa-Breda et al. compared a large cohort of NTG and POAG patients using several different vascular-related devices, and found that NTG patients displayed more signs of vascular dysfunction.⁸²

5. Vascular dysregulation

It has been suggested that vascular dysregulation is a major factor in GON pathogenesis in NTG.^{83,84} Some NTG patients displayed changes in OBF autoregulation; moreover, they also showed more extensive vascular dysfunction known as primary vascular dysregulation (PVD). Primary vascular dysregulation syndrome, which was first proposed by Josef Flammer, describes a phenotype comprising PVD together with a cluster of associated symptoms and signs that can occur in healthy subjects and those with disease.⁷⁹ This syndrome was then later renamed "Flammer Syndrome" by K. Konieczka et al..⁸⁵

5.1. Flammer syndrome

Flammer syndrome occurs more prevalently among females, slender subjects, Asians, those with indoor jobs, and academics.⁸⁶ These symptoms begin to manifest in adolescence and mitigate with age. Moreover, Flammer syndrome has a hereditary component and is not caused by another disease.⁸⁵ There is currently no single gold standard for the diagnosis of Flammer syndrome. However, in clinical practice, testing may not always be necessary because there are certain signs and symptoms that clearly indicate Flammer syndrome, including: 1) Cold extremities (cold hands or feet); 2) Low BP; 3) Being exceptionally sensitive (smell, pain, vibration, high altitude, response to drugs, etc.); 4) Shifted circadian rhythm; 5) Prolonged sleep onset time; 6) Reduced feelings of thirst.⁷⁹

Regarding the circulation, subjects with Flammer syndrome have an inborn predisposition to respond differently to all types of stimuli

(including cold, mechanical or emotional stress, and particularly stimuli related to blood vessels). The most clear pathological reaction is vasoconstriction (vasospasm). Due to vascular disorders, the response of Flammer syndrome patients to BP and IOP is also altered, resulting in instability of the OPP and OBF. Morphologically, the retinal vessels demonstrate a higher level of irregularity and are stiffer, with a reduced vasodilation occurring in response to flickering light.⁸⁷ In a provocation with hand-grip test, their choroidal vessels showed a more vasoconstrictive response compared with control subjects.⁸⁸ This complex regulatory dysfunction results in incomplete adaptation to stimuli which in turn, leads to unstable ocular perfusion.

That Flammer syndrome is a risk factor for GON may explain the risk factors for NTG such as sex and ethnic origin. Indeed, Flammer syndrome is also a main cause of splinter hemorrhages at the border of the ONH, which may explain why ONH hemorrhages occur frequently in NTG patients. Optic disc hemorrhages are commonly observed in glaucoma patients, particularly in NTG, and occur more frequently in Flammer syndrome patients.⁸⁹ Josef Flammer suggested that this may be a result of a disturbed blood-retina barrier.^{72,90} Subjects with Flammer syndrome also exhibit increased retinal venous pressure (RVP). High RVP can reduce the PP and therefore reduce circulation of both the retina and the ONH.⁹¹ Such dysregulation is probably the result of a local increase in vasoactive factors, including endothelin-1 (ET-1). Compared with healthy controls, higher ET-1 levels were observed in glaucoma patients, particularly those with NTG who usually suffer from Flammer syndrome.^{92,93} Moreover, Flammer syndrome in NTG is also associated with retinal astrocyte activation, increased oxidative stress, and diffuse visual field defects.⁸⁵ The complex regulatory dysfunction can lead to an incomplete adaptation to stimuli, resulting in unstable ocular perfusion. This instable blood flow leads to mild but repeated reperfusion, which contributes to glaucomatous damage through oxidative stress.⁹⁴

5.2. Vasospasm and migraine

Migraine is currently considered to be a neurovascular syndrome, which is associated with transient vasospastic episodes, leading to the impairment of autoregulation of blood flow in the central nervous system.⁹⁵ There is an association between migraine and Flammer syndrome. Although migraine and Flammer syndrome have some common features, there are some distinct differences. Vasoconstriction is the most obvious pathological reaction in Flammer syndrome, hence, Flammer syndrome was previously classified as a vasospastic syndrome.⁸⁵ Ischemia due to vasoconstriction is considered to be a potential risk factor for the development of glaucomatous visual field damage.^{79,96} Vasospasm refers to the reversible disproportionate contraction of the arteries, resulting in a temporary decrease or shortage of the blood supply to the corresponding organ. Vasospasm is common and associated with a variety of diseases, for example, in the retina, particularly in the case of migraines.⁸⁵ Previous studies have demonstrated that vasospasm leads to environmental disturbances in blood flow, increasing the vulnerability of the ONH to vascular challenges, leading to instability of perfusion, changes in ischemia, reperfusion injury, and the loss of ONH axons.⁹⁷ In addition, migraines can cause a temporary decrease of OBF.⁹⁸ Gramer et al. found a relationship between migraine and vasospasm in a large number of glaucoma patients. They also found that migraine was associated more with NTG than HTG.⁹⁹ To date, the association of migraine and NTG has been formally confirmed in many studies, with migraines being a risk factor for NTG progression.^{27,100,101} Moreover, it has been reported that subjects with vasospastic disorders, including Raynaud's phenomenon, also have a prevalence of migraine.¹⁰² Consequently, both migraine and vasospasm may be risk factors for NTG.

In addition, abnormal variations in blood vessel diameter are common in peripheral organs, including the fingers and eyes of individuals with migraine.^{79,103} These blood vessel alterations are assumed to be a sign of vasospasm, or more broadly, for Flammer syndrome.⁸⁵ Retinal vascular dysregulation and poor blood flow at the ONH have been

implicated in NTG; several studies have proposed that NTG and migraine have a common vasospastic mechanism.¹⁰⁴ Flammer syndrome subjects suffer more frequently from migraines. It has been reported that vasospasm could underlie the occlusions of the retinal vasculature in migraine patients.¹⁰⁵ Dadaci et al. hypothesized that the expression of neurogenic inflammation in the eye contributes to the autonomic dysfunction and alteration of ocular circulation in migraine in glaucoma.¹⁰⁶ It is true that autonomic nervous dysfunction is present in glaucoma, PVD, and migraine. But in these diseases, clear dysregulations were also found of the retinal blood vessels, although they are not autonomically innervated. A decreased blood flow in the ocular artery is associated with glaucoma progression. A history of migraines constitutes an important and independent risk factor for optic disc hemorrhage.²⁷ Furthermore, NTG patients with a concurrent history of migraine are more likely to progress in terms of visual field defects.¹⁰⁰ These findings indicated that the vasculature remains a potential factor in the pathogenesis of both NTG and migraine.

5.3. Reperfusion damage

A mild but recurrent BF decrease is primarily due to the fluctuation of OPP and disturbance of autoregulation, resulting in an unstable and insufficient oxygen supply, thus increasing local mitochondrial oxidative stress.^{107,108} Oxidative stress is induced by an imbalance between the production of reactive oxygen species and their elimination by antioxidants, which results in damage to cellular macromolecules and ultimately leads to cellular and tissue dysfunction and even mortality.¹⁰⁹ Reperfusion caused by unstable ocular perfusion is the major cause of oxidative stress, mainly occurring in the ONH. Perfusion instability is present both in patients with a high IOP or a low IOP that exceeds their ability to regulate, as well as in patients with a normal IOP or BP (if the patient has disturbed autoregulation). Disturbed autoregulation occurs predominantly in patients with Flammer syndrome. By interfering with the autoregulation, the sensitivity to a BP reduction is increased.^{40,72} Increasing evidence has demonstrated that oxidative stress is involved in the loss of RGCs in NTG, and plays an important role in GON pathogenesis.¹⁰⁹⁻¹¹¹

Systemic DNA damage as the pathomechanism of glaucoma is identifiable by the markers of oxidative stress, including urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and total antioxidant status. Yuki et al. found that the levels of urinary 8-OHdG/creatinine were increased significantly in subjects with progressive NTG compared with patients with nonprogressive NTG.¹¹² Urinary 8-OHdG levels have recently been reported to be associated with the ONH circulation, particularly in early-NTG patients.¹¹³ Mozaffarieh et al. revealed that POAG patients with PVD have a significantly higher rate of DNA breaks in circulating lymphocytes than both POAG patients without PVD and healthy controls.¹¹⁴ Although many details of the relationship between oxidative stress and NTG remain strongly debated, further studies will reveal the association between DNA damage and NTG. Unlike damaged DNA, damaged proteins cannot be repaired. Wunderlich et al. suggested that the upregulation of 20S proteasome alpha-subunit levels indicated an increased oxidative stress in glaucoma patients.¹¹⁵

The microcirculation is mainly regulated via endothelial-derived vasoactive factors, including ET-1 and nitric oxide (NO). This regulation of endothelial cells is crucial to the ability of cells to adapt to variations in PP (autoregulation).¹¹⁶ ET-1 significantly induces vasoconstriction by interacting with its receptors. Various studies demonstrated a systemic endothelium-derived vascular dysfunction in NTG.¹¹⁷⁻¹¹⁹ Oxidative stress leads to elevated ET-1 expression. A large number of studies have shown an elevated ET-1 level in glaucoma patients, particularly in patients with progressive neuropathy despite having a normalized IOP.^{120, 121} By contrast, NO primarily promotes vasodilation. Astrocyte activation leads to increased NO production, and if accompanied by a high concentration of superoxide (O₂⁻) due to reperfusion, highly damaging peroxynitrite can be produced.^{122, 123}

Neufeld et al. suggest that the glaucomatous ONH is exposed to excessive NO levels, which may be neurodestructive, locally, to the axons of the RGCs.¹²⁴ Metalloproteinases are upregulated in the ONH of glaucoma patients. An upregulation of matrix metalloprotein-9 was found in circulating lymphocytes in NTG patients, which may be a consequence of reperfusion injury.¹²⁵

6. Regulation of ocular blood flow

The mainstream treatment for all types of glaucoma, including NTG, is IOP reduction. The Collaborative Normal Tension Glaucoma Study demonstrated that a 30% IOP reduction may slow NTG progression.¹²⁶ Some subjects may continue to progress even if their IOP is on target, leading to the need to develop new treatments. With the advances in the understanding of NTG pathogenesis, several new therapeutic approaches have been developed, some of which are already in clinical use, while others are still under experimental research. The IOP-independent management of NTG, including vascular regulation and neuroprotection, provide alternative therapeutic options for NTG patients.

All theories regarding NTG development and the vascular etiology derive a general conclusion, that is, there is an interruption of the blood flow in the optic nerve.¹²⁷ Ischemic changes involved are not only the result of an insufficient blood flow, but also an imbalance or fluctuation of the circulation around the optic nerve, which leads to ischemia-reperfusion injury. Therefore, several drugs that act on OBF have been investigated. Gasser and Flammer first investigated the calcium channel blockers (CCBs) as potential therapeutic applications to improve ocular perfusion.¹²⁸ Since then, a range of reports found that CCBs, including nimodipine, normalize the retinal circulation together with vasospastic symptoms and increase the ONH and choroidal blood flow in NTG patients.^{129,130} Nimodipine also has the capacity to reverse the effects of ET-1 on ocular blood vessels.¹³¹ Furthermore, CCBs are also believed to have neuroprotective properties.¹³² Toriu et al. reported that lomerizine protects neuronal cells against retinal neurotoxicity both in vitro and in vivo.¹³³ However, there is concern that a systemic hypotensive effect, via peripheral vasodilation in the case of CCBs, may exacerbate glaucomatous damage by decreasing the diastolic OPP to the optic nerve.¹³⁴ Under normal condition, the doses we used were very low that hardly ever lower BP but it does have an effect on NTG.¹³⁵ In addition, some side effects, including peripheral edema, may limit the utility of CCBs for certain patients.¹³⁶

An additional component of NTG treatment is neuroprotection. Many researchers are currently investigating the potential use of natural substances as an adjuvant therapy for glaucoma. Ginkgo biloba extract (GBE) is a phytochemical that is widely used in medicine. Several studies suggested that, as a neuroprotective and antioxidative agent, it shows a benefit in the management of neurological and vascular conditions.¹³⁷ Chung et al. revealed the neuroprotective properties of a ginkgo extract (EGb761) in brain ischemia.¹³⁸ In clinical trials, GBE was shown to delay the progression of visual field defects in NTG patients.¹³⁹ It was also found that GBE improved peripapillary blood flow in NTG patients compared to a control group.¹⁴⁰ Another phytochemical currently under investigation is resveratrol, which is found in fruits and red wine, and is reported to have antioxidative and anti-inflammatory properties.^{141,142} Resveratrol is currently being investigated for neuroprotective qualities in the treatment of glaucoma and other ophthalmic diseases.¹⁴³

7. Vascular treatment

Most of the literature emphasizes that IOP lowering is the only proven glaucoma therapy, and occasionally points out that blood flow evaluation is not useful in glaucoma because of the lack of therapeutic consequences.⁴³ Is such a statement still fully valid?

Pharmacological treatment of the vascular disorders in glaucoma requires a suitable drug and controlled long-term studies showing that such treatment improves prognosis. A prerequisite for the development

of such a drug by the pharmaceutical industry is an agreement in the scientific community that a vascular problem exist and is relevant to the disease. While individual investigators have described circulatory disturbances in glaucoma for decades,³⁵ it is only with the recent introduction of OCTA that this has become apparent to all ophthalmologists.⁵⁸

Another point of contention has been whether the reduction in blood flow is only secondary to the glaucoma damage or increased intraocular pressure, or whether it is primary. There is no doubt that a loss of substance decreases blood flow. It is also clear that increased IOP decreases blood flow, especially when autoregulation is impaired. However, the fact that ocular blood flow disturbance often precedes visual field damage, that blood flow disturbance can be measured not only in the eye but also in other organs of glaucoma patients, and that a short-term pharmacologically induced increase in blood flow leads to a transient improvement in visual fields,¹⁴⁴ whereas an induced decrease in blood flow leads to a transient deterioration of visual fields,¹⁴⁵ speaks in favor of an additional primary vascular component.

However, in order to develop an effective drug, we also need to know the nature of the perfusion disorder in glaucoma. It is well known that low PP reduces blood flow to the eye, especially when autoregulation is disturbed and thus worsens the prognosis. The question here is which is more promising, increasing PP or improving regulation. Severe atherosclerosis can also reduce ocular perfusion, but it is hardly treatable. However, relatively new and therapeutically promising is the observation that vascular dysregulation is a common cause of NTG.⁷⁹ While smaller, uncontrolled studies have already shown that regulation can be improved,¹²⁸ larger controlled studies are imperative. We illustrate this with the example of increased RVP. The retinal veins are often dysregulated in glaucoma patients. As a result, venous pressure increases and PP decreases.⁹¹ A first promising study has shown that this RVP can be lowered with vitamin supplementation containing L-methylfolate (Ocufofin® forte).^{146,147}

While we still have a long way to go before we have a widely accepted, evidence-based vascular treatment for glaucoma, ophthalmologists already have therapeutic options other than only further lowering intraocular pressure in patients with progressive glaucoma damage despite well-controlled IOP.¹³⁵

8. Conclusions

In summary, NTG is a multifactorial and complicated disease, the pathogenesis of which involves vascular factors. OBF is the main factor contributing to the progression of NTG-related GON. PVD, the essential component of Flammer syndrome, leads to OBF instability in the ONH, which in turn locally increases oxidative stress. The methods to evaluate OBF are developing with the greater understanding of the role of OBF in NTG. As described in this review, the novel methodologies employed have their own unique advantages and can be used as reliable measurement methods of OBF status. Recently, accumulated evidence has suggested that an association of compromised vasculature with NTG pathogenesis urges us to pay greater attention to IOP-independent therapy of NTG, in addition to decreasing the IOP.

Study Approval

Not Applicable.

Author Contributions

The authors confirm contribution to the paper as follows: conceived and designed the review: XDW, KK, KJW, JF, KY; searched and selected references of the review: XDW, KK, XL, MC; Drafting the manuscript: XDW, KK; All authors reviewed and approved the final version of the manuscript.

Acknowledgements

Thanks to all the peer reviewers for their opinions and suggestions.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare that they have no competing interests.

Editorship Disclosure

Given his role as Editor-in-Chief, Ke Yao had no involvement in the peer-review of this article and has no access to information regarding its peer-review. Full responsibility for the editorial process for this article was delegated to Prof. Andrzej Grzybowski.

Abbreviations

| | |
|----------------|---|
| NTG | Intraocular Pressure |
| OBF | Ocular Blood Flow |
| GON | Glaucomatous Optic Neuropathy |
| ONH | Optic Nerve Head |
| RGCs | Retinal Ganglion Cells |
| RNFL | Retinal Nerve Fiber Layer |
| POAG | Primary Open-Angle Glaucoma |
| HTG | High Tension Glaucoma |
| OPP | Ocular Perfusion Pressure |
| CDI | Color Doppler Imaging |
| Doppler FD-OCT | Doppler Fourier Domain Optical Coherence Tomography |
| OCTA | Optical Coherence Tomography Angiography |
| BP | Blood Pressure |
| RVP | Retinal Venous Pressure |
| PVD | Primary Vascular Dysregulation |
| ROS | Reactive Oxygen Species |
| 8-OHdG | 8-Hydroxy-2'-Deoxyguanosine |
| ET-1 | Endothelin-1 |
| NO | Nitric Oxide |
| MMP | Matrix Metalloprotein |
| CCBs | Calcium Channel Blockers |
| GBE | Ginkgo Biloba Extract |

References

- Jonas JB, Aung T, Bourne RR, et al. Glaucoma. *Lancet*. 2017;390(10108):2183–2193. [https://doi.org/10.1016/s0140-6736\(17\)31469-1](https://doi.org/10.1016/s0140-6736(17)31469-1).
- Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121(11):2081–2090. <https://doi.org/10.1016/j.ophtha.2014.05.013>.
- Schuster AK, Erb C, Hoffmann EM, et al. The diagnosis and treatment of glaucoma. *Dtsch Arztebl Int*. 2020;117(13):225–234. <https://doi.org/10.3238/arztebl.2020.0225>.
- Weinreb RN, Leung CK, Crowston JG, et al. Primary open-angle glaucoma. *Nat Rev Dis Prim*. 2016;2:16067. <https://doi.org/10.1038/nrdp.2016.67>.
- Esporcatte BL, Tavares IM. Normal-tension glaucoma: an update. *Arq Bras Oftalmol*. 2016;79(4):270–276. <https://doi.org/10.5935/0004-2749.20160077>.
- Zhang HJ, Mi XS, So KF. Normal tension glaucoma: from the brain to the eye or the inverse? *Neural Regen Res*. 2019;14(11):1845–1850. <https://doi.org/10.4103/1673-5374.259600>.
- Trivli A, Koliarakis I, Terzidou C, et al. Normal-tension glaucoma: pathogenesis and genetics. *Exp Ther Med*. 2019;17(1):563–574. <https://doi.org/10.3892/etm.2018.7011>.
- Killer HE, Pircher A. Normal tension glaucoma: review of current understanding and mechanisms of the pathogenesis. *Eye (Lond)*. 2018;32(5):924–930. <https://doi.org/10.1038/s41433-018-0042-2>.
- Harrington DO. The pathogenesis of the glaucoma field: clinical evidence that circulatory insufficiency in the optic nerve is the primary cause of visual field loss in glaucoma. *Am J Ophthalmol*. 1959;47(5 Pt 2):177–185.
- Ernest PJ, Schouten JS, Beckers HJ, et al. An evidence-based review of prognostic factors for glaucomatous visual field progression. *Ophthalmology*. 2013;120(3):512–519. <https://doi.org/10.1016/j.ophtha.2012.09.005>.
- Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol*. 2002;120(10):1268–1279. <https://doi.org/10.1001/archophth.120.10.1268>.
- Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. *Surv Ophthalmol*. 2008;53(suppl 1). <https://doi.org/10.1016/j.survophthal.2008.08.006>. S3-10.
- Nakazawa T, Fukuchi T. What is glaucomatous optic neuropathy? *Jpn J Ophthalmol*. 2020;64(3):243–249. <https://doi.org/10.1007/s10384-020-00736-1>.
- Lee K, Yang H, Kim JY, et al. Risk factors associated with structural progression in normal-tension glaucoma: intraocular pressure, systemic blood pressure, and myopia. *Invest Ophthalmol Vis Sci*. 2020;61(8):35. <https://doi.org/10.1167/jovs.61.8.35>.
- Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. *Ophthalmology*. 2007;114(2):205–209. <https://doi.org/10.1016/j.ophtha.2006.07.060>.
- Chan EW, Li X, Tham YC, et al. Glaucoma in Asia: regional prevalence variations and future projections. *Br J Ophthalmol*. 2016;100(1):78–85. <https://doi.org/10.1136/bjophthalmol-2014-306102>.
- Zhao J, Solano MM, Oldenburg CE, et al. Prevalence of normal-tension glaucoma in the Chinese population: a systematic review and meta-analysis. *Am J Ophthalmol*. 2019;199:101–110. <https://doi.org/10.1016/j.ajo.2018.10.017>.
- Cho HK, Kee C. Population-based glaucoma prevalence studies in Asians. *Surv Ophthalmol*. 2014;59(4):434–447. <https://doi.org/10.1016/j.survophthal.2013.09.003>.
- Park HY, Lee K, Park CK. Optic disc torsion direction predicts the location of glaucomatous damage in normal-tension glaucoma patients with myopia. *Ophthalmology*. 2012;119(9):1844–1851. <https://doi.org/10.1016/j.ophtha.2012.03.006>.
- Park HL, Shin DY, Jeon SJ, et al. Predicting the development of normal tension glaucoma and related risk factors in normal tension glaucoma suspects. *Sci Rep*. 2021;11(1):16697. <https://doi.org/10.1038/s41598-021-95984-7>.
- Sohn SW, Song JS, Kee C. Influence of the extent of myopia on the progression of normal-tension glaucoma. *Am J Ophthalmol*. 2010;149(5):831–838. <https://doi.org/10.1016/j.ajo.2009.12.033>.
- Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. *Ophthalmology*. 2004;111(9):1627–1635. <https://doi.org/10.1016/j.ophtha.2004.02.017>.
- Sia DI, Edussuriya K, Sennanayake S, et al. Prevalence of and risk factors for primary open-angle glaucoma in central Sri Lanka: the Kandy eye study. *Ophthalmic Epidemiol*. 2010;17(4):211–216. <https://doi.org/10.3109/09286586.2010.483753>.
- Gasser, ORGUL, FLAMMER. Female preponderance in normal-tension glaucoma. *Annals of Ophthalmology Glaucoma*. 1995;27(6):355–359.
- Mozaffarieh M, Gasio PF, Schötzau A, et al. Thermal discomfort with cold extremities in relation to age, gender, and body mass index in a random sample of a Swiss urban population. *Popul Health Metrics*. 2010;8(1):1–5.
- Ozturker ZK, Munro K, Gupta N. Optic disc hemorrhages in glaucoma and common clinical features. *Can J Ophthalmol*. 2017;52(6):583–591. <https://doi.org/10.1016/j.jco.2017.04.011>.
- Furlanetto RL, De Moraes CG, Teng CC, et al. Risk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study. *Am J Ophthalmol*. 2014;157(5):945–952. <https://doi.org/10.1016/j.ajo.2014.02.009>.
- Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma? *Curr Opin Ophthalmol*. 2008;19(2):85–88. <https://doi.org/10.1097/ICU.0b013e3282f3919b>.
- Nitta K, Sugiyama K, Wajima R, et al. Associations between changes in radial peripapillary capillaries and occurrence of disc hemorrhage in normal-tension glaucoma. *Graefes Arch Clin Exp Ophthalmol*. 2019;257(9):1963–1970. <https://doi.org/10.1007/s00417-019-04382-3>.
- Quigley HA, Addicks EM, Green WR, et al. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. *Arch Ophthalmol*. 1981;99(4):635–649. <https://doi.org/10.1001/archophth.1981.03930010635009>.
- Kim YD, Han SB, Park KH, et al. Risk factors associated with optic disc haemorrhage in patients with normal tension glaucoma. *Eye (Lond)*. 2010;24(4):567–572. <https://doi.org/10.1038/eye.2009.163>.
- Soares AS, Artes PH, Andreou P, et al. Factors associated with optic disc hemorrhages in glaucoma. *Ophthalmology*. 2004;111(9):1653–1657. <https://doi.org/10.1016/j.ophtha.2004.03.023>.
- Jung Y, Han K, Park H, et al. Type 2 diabetes mellitus and risk of open-angle glaucoma development in Koreans: an 11-year nationwide propensity-score-matched study. *Diabetes Metab*. 2018;44(4):328–332. <https://doi.org/10.1016/j.diabet.2017.09.007>.
- Nakamura M, Kanamori A, AJOJidoJooZFA Negi. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. *Ophthalmologica*. 2005;219(1):1–10. <https://doi.org/10.1159/000081775>.
- Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. *Prog Retin Eye Res*. 2002;21(4):359–393. [https://doi.org/10.1016/s1350-9462\(02\)00008-3](https://doi.org/10.1016/s1350-9462(02)00008-3).

36. Grieshaber MC, Flammer J. Blood flow in glaucoma. *Curr Opin Ophthalmol*. 2005; 16(2):79–83. <https://doi.org/10.1097/01.icu.0000156134.38495.0b>.
37. Flammer J, Orgül S. Optic nerve blood-flow abnormalities in glaucoma. *Prog Retin Eye Res*. 1998;17(2):267–289. [https://doi.org/10.1016/s1350-9462\(97\)00006-2](https://doi.org/10.1016/s1350-9462(97)00006-2).
38. Levine RM, Yang A, Brahma V, et al. Management of blood pressure in patients with glaucoma. *Curr Cardiol Rep*. 2017;19(11):109. <https://doi.org/10.1007/s11886-017-0927-x>.
39. Fan N, Wang P, Tang L, et al. Ocular blood flow and normal tension glaucoma. *BioMed Res Int*. 2015;2015:308505. <https://doi.org/10.1155/2015/308505>.
40. Flammer J, Mozaffarieh M. Autoregulation, a balancing act between supply and demand. *Can J Ophthalmol*. 2008;43(3):317–321. <https://doi.org/10.3129/i08-056>.
41. Xu H, Zhai R, Zong Y, et al. Comparison of retinal microvascular changes in eyes with high-tension glaucoma or normal-tension glaucoma: a quantitative optical coherence tomography angiographic study. *Graefes Arch Clin Exp Ophthalmol*. 2018; 256(6):1179–1186. <https://doi.org/10.1007/s00417-018-3930-z>.
42. Luo X, Shen YM, Jiang MN, et al. Ocular blood flow autoregulation mechanisms and methods. *J Ophthalmol*. 2015;2015:864871. <https://doi.org/10.1155/2015/864871>.
43. Caprioli J, Coleman AL. Blood pressure, perfusion pressure, and glaucoma. *Am J Ophthalmol*. 2010;149(5):704–712. <https://doi.org/10.1016/j.ajo.2010.01.018>.
44. Matthiessen ET, Zeitz O, Richard G, et al. Reproducibility of blood flow velocity measurements using colour decoded Doppler imaging. *Eye (Lond)*. 2004;18(4): 400–405. <https://doi.org/10.1038/sj.eye.6700651>.
45. Butt Z, McKillop G, O'Brien C, et al. Measurement of ocular blood flow velocity using colour Doppler imaging in low tension glaucoma. *Eye (Lond)*. 1995;9(Pt 1): 29–33. <https://doi.org/10.1038/eye.1995.4>.
46. Butt Z, O'Brien C, McKillop G, et al. Color Doppler imaging in untreated high- and normal-pressure open-angle glaucoma. *Invest Ophthalmol Vis Sci*. 1997;38(3): 690–696.
47. Schuman JS, Hee MR, Arya AV, et al. Optical coherence tomography: a new tool for glaucoma diagnosis. *Curr Opin Ophthalmol*. 1995;6(2):89–95. <https://doi.org/10.1097/00055735-199504000-00014>.
48. Wang Y, Bower BA, Izatt JA, et al. Retinal blood flow measurement by circumpapillary Fourier domain Doppler optical coherence tomography. *J Biomed Opt*. 2008;13(6), 064003. <https://doi.org/10.1117/1.2998480>.
49. Leitgeb RA, Schmetterer L, Hitzenberger CK, et al. Real-time measurement of in vitro flow by Fourier-domain color Doppler optical coherence tomography. *Opt Lett*. 2004;29(2):171–173. <https://doi.org/10.1364/ol.29.000171>.
50. Srinivas S, Tan O, Wu S, et al. Measurement of retinal blood flow in normal Chinese-American subjects by Doppler Fourier-domain optical coherence tomography. *Invest Ophthalmol Vis Sci*. 2015;56(3):1569–1574. <https://doi.org/10.1167/iovs.14-15038>.
51. Wang Y, Fawzi AA, Varma R, et al. Pilot study of optical coherence tomography measurement of retinal blood flow in retinal and optic nerve diseases. *Invest Ophthalmol Vis Sci*. 2011;52(2):840–845. <https://doi.org/10.1167/iovs.10-5985>.
52. Arnold AC. Fluorescein angiographic characteristics of the optic disc in ischemic and glaucomatous optic neuropathy. *Curr Opin Ophthalmol*. 1995;6(2):30–35. <https://doi.org/10.1097/00055735-199504000-00006>.
53. Arend O, Plange N, Sponsel WE, et al. Pathogenetic aspects of the glaucomatous optic neuropathy: fluorescein angiographic findings in patients with primary open angle glaucoma. *Brain Res Bull*. 2004;62(6):517–524. <https://doi.org/10.1016/j.brainresbull.2003.07.008>.
54. Plange N, Kaup M, Weber A, et al. Fluorescein filling defects and quantitative morphologic analysis of the optic nerve head in glaucoma. *Arch Ophthalmol*. 2004; 122(2):195–201. <https://doi.org/10.1001/archoph.122.2.195>.
55. Plange N, Kaup M, Remky A, et al. Prolonged retinal arteriovenous passage time is correlated to ocular perfusion pressure in normal tension glaucoma. *Graefes Arch Clin Exp Ophthalmol*. 2008;246(8):1147–1152. <https://doi.org/10.1007/s00417-008-0807-6>.
56. Bojikian KD, Chen PP, Wen JC. Optical coherence tomography angiography in glaucoma. *Curr Opin Ophthalmol*. 2019;30(2):110–116. <https://doi.org/10.1097/icu.0000000000000554>.
57. Werner AC, Shen LQ. A review of OCT angiography in glaucoma. *Semin Ophthalmol*. 2019;34(4):279–286. <https://doi.org/10.1080/08820538.2019.1620807>.
58. Liu L, Jia Y, Takusagawa HL, et al. Optical coherence tomography angiography of the peripapillary retina in glaucoma. *JAMA Ophthalmol*. 2015;133(9):1045–1052. <https://doi.org/10.1001/jamaophthalmol.2015.2225>.
59. Scripsema NK, Garcia PM, Bavier RD, et al. Optical coherence tomography angiography analysis of perfused peripapillary capillaries in primary open-angle glaucoma and normal-tension glaucoma. *Invest Ophthalmol Vis Sci*. 2016;57(9): Oct611–oct620. <https://doi.org/10.1167/iovs.15-18945>.
60. Van Melkebeke L, Barbosa-Breda J, Huygens M, et al. Optical coherence tomography angiography in glaucoma: a review. *Ophthalmic Res*. 2018;60(3): 139–151. <https://doi.org/10.1159/000488495>.
61. Katai N, Yoshimura N. Apoptotic retinal neuronal death by ischemia-reperfusion is executed by two distinct caspase family proteases. *Invest Ophthalmol Vis Sci*. 1999; 40(11):2697–2705.
62. Yamazaki Y, Drance SM. The relationship between progression of visual field defects and retrobulbar circulation in patients with glaucoma. *Am J Ophthalmol*. 1997;124(3):287–295. [https://doi.org/10.1016/s0002-9394\(14\)70820-7](https://doi.org/10.1016/s0002-9394(14)70820-7).
63. Orgül S, Gugleta K, Flammer J. Physiology of perfusion as it relates to the optic nerve head. *Surv Ophthalmol*. 1999;43(Suppl 1):S17–S26. [https://doi.org/10.1016/s0039-6257\(99\)00009-0](https://doi.org/10.1016/s0039-6257(99)00009-0).
64. Ramdas WD, Wolfs RC, Hofman A, et al. Ocular perfusion pressure and the incidence of glaucoma: real effect or artifact? The Rotterdam Study. *Invest Ophthalmol Vis Sci*. 2011;52(9):6875–6881. <https://doi.org/10.1167/iovs.11-7376>.
65. Kim KE, Oh S, Baek SU, et al. Ocular perfusion pressure and the risk of open-angle glaucoma: systematic review and meta-analysis. *Sci Rep*. 2020;10(1):10056. <https://doi.org/10.1038/s41598-020-66914-w>.
66. Sung KR, Cho JW, Lee S, et al. Characteristics of visual field progression in medically treated normal-tension glaucoma patients with unstable ocular perfusion pressure. *Invest Ophthalmol Vis Sci*. 2011;52(2):737–743. <https://doi.org/10.1167/iovs.10-5351>.
67. Anderson Douglas R. Glaucoma, conceptions of a disease: pathogenesis, diagnosis, therapy. *Am J Ophthalmol*. 1979;88(1):138–139.
68. Flammer J. Measuring and treating retinal venous pressure: efforts and benefits. *hb TIMES Schw Aerzte*. 2021;(3):60–62. <https://doi.org/10.36000/hbT.2021.03.0XX>.
69. Kaiser HJ, Flammer J. Systemic hypotension: a risk factor for glaucomatous damage? *Ophthalmologica*. 1991;203(3):105–108. <https://doi.org/10.1159/000310234>.
70. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. *Ophthalmology*. 2008;115(1):85–93. <https://doi.org/10.1016/j.ophtha.2007.03.017>.
71. Choi J, Kim KH, Jeong J, et al. Circadian fluctuation of mean ocular perfusion pressure is a consistent risk factor for normal-tension glaucoma. *Invest Ophthalmol Vis Sci*. 2007;48(1):104–111. <https://doi.org/10.1167/iovs.06-0615>.
72. Flammer J, Konieczka K, Bruno RM, et al. The eye and the heart. *Eur Heart J*. 2013; 34(17):1270–1278. <https://doi.org/10.1093/eurheartj/ehd023>.
73. Charlson ME, de Moraes CG, Link A, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. *Ophthalmology*. 2014;121(10): 2004–2012. <https://doi.org/10.1016/j.ophtha.2014.04.016>.
74. Raman P, Suliman NB, Zahari M, et al. Low nocturnal diastolic ocular perfusion pressure as a risk factor for NTG progression: a 5-year prospective study. *Eye (Lond)*. 2018;32(7):1183–1189. <https://doi.org/10.1038/s41433-018-0057-8>.
75. Jin SW, Noh SY. Long-term clinical course of normal-tension glaucoma: 20 Years of experience. *J Ophthalmol*. 2017;2017:2651645. <https://doi.org/10.1155/2017/2651645>.
76. Bowe A, Grünig M, Schubert J, et al. Circadian variation in arterial blood pressure and glaucomatous optic neuropathy—A systematic review and meta-analysis. *Am J Hypertens*. 2015;28(9):1077–1082. <https://doi.org/10.1093/ajh/hpv016>.
77. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? *Surv Ophthalmol*. 2007;52(Suppl 2):S162–S173. <https://doi.org/10.1016/j.survophthal.2007.08.012>.
78. Orgül S, Kaiser HJ, Flammer J, et al. Systemic blood pressure and capillary blood-cell velocity in glaucoma patients: a preliminary study. *Eur J Ophthalmol*. 1995;5(2): 88–91.
79. Flammer J, Konieczka K, Flammer AJ. The primary vascular dysregulation syndrome: implications for eye diseases. *EPMA J*. 2013;4(1):14. <https://doi.org/10.1186/1878-5085-4-14>.
80. Ramli N, Nurull BS, Hairi NN, et al. Low nocturnal ocular perfusion pressure as a risk factor for normal tension glaucoma. *Prev Med*. 2013;57(Suppl):S47–S49. <https://doi.org/10.1016/j.ypmed.2013.01.007>.
81. Lindemann F, Kuersten D, Koch E, et al. Blood pressure and heart rate variability in primary open-angle glaucoma and normal tension glaucoma. *Curr Eye Res*. 2018; 43(12):1507–1513. <https://doi.org/10.1080/02713683.2018.1506036>.
82. Barbosa-Breda J, Van Keer K, Abegão-Pinto L, et al. Improved discrimination between normal-tension and primary open-angle glaucoma with advanced vascular examinations - the Leuven Eye Study. *Acta Ophthalmol*. 2019;97(1):e50–e56. <https://doi.org/10.1111/aos.13809>.
83. Flammer J. The vascular concept of glaucoma. *Surv Ophthalmol*. 1994;38(suppl 1). [https://doi.org/10.1016/0039-6257\(94\)90041-8](https://doi.org/10.1016/0039-6257(94)90041-8). S3-6.
84. Emre M, Orgül S, Gugleta K, et al. Ocular blood flow alteration in glaucoma is related to systemic vascular dysregulation. *Br J Ophthalmol*. 2004;88(5):662–666. <https://doi.org/10.1136/bjo.2003.032110>.
85. Konieczka K, Ritch R, Traverso CE, et al. Flammer syndrome. *EPMA J*. 2014;5(1): 11. <https://doi.org/10.1186/1878-5085-5-11>.
86. Mozaffarieh M, Flammer J. New insights in the pathogenesis and treatment of normal tension glaucoma. *Curr Opin Pharmacol*. 2013;13(1):43–49. <https://doi.org/10.1016/j.coph.2012.10.001>.
87. Gugleta K, Zawinka C, Rickenbacher I, et al. Analysis of retinal vasodilation after flicker light stimulation in relation to vasospastic propensity. *Invest Ophthalmol Vis Sci*. 2006;47(9):4034–4041. <https://doi.org/10.1167/iovs.06-0351>.
88. Gugleta K, Orgül S, Hasler PW, et al. Choroidal vascular reaction to hand-grip stress in subjects with vasospasm and its relevance in glaucoma. *Invest Ophthalmol Vis Sci*. 2003;44(4):1573–1580. <https://doi.org/10.1167/iovs.02-0521>.
89. Grieshaber MC, Terhorst T, Flammer J. The pathogenesis of optic disc splinter haemorrhages: a new hypothesis. *Acta Ophthalmol Scand*. 2006;84(1):62–68. <https://doi.org/10.1111/j.1600-0420.2005.00590.x>.
90. Grieshaber MC, Flammer J. Does the blood-brain barrier play a role in Glaucoma? *Surv Ophthalmol*. 2007;52(Suppl 2):S115–S121. <https://doi.org/10.1016/j.survophthal.2007.08.005>.
91. Flammer J, Konieczka K. Retinal venous pressure: the role of endothelin. *EPMA J*. 2015;6:21. <https://doi.org/10.1186/s13167-015-0043-1>.
92. Kaiser HJ, Flammer J, Wenk M, et al. Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. *Graefes Arch Clin Exp Ophthalmol*. 1995;233(8):484–488. <https://doi.org/10.1007/bf00183429>.

93. Li S, Zhang A, Cao W, et al. Elevated plasma endothelin-1 levels in normal tension glaucoma and primary open-angle glaucoma: a meta-analysis. *J Ophthalmol.* 2016; 2016:2678017. <https://doi.org/10.1155/2016/2678017>.
94. Konieczka K, Erb C. Diseases potentially related to Flammer syndrome. *EPMA J.* 2017;8(4):327–332. <https://doi.org/10.1007/s13167-017-0116-4>.
95. Silberstein SD. Migraine. *Lancet.* 2004;363(9406):381–391. [https://doi.org/10.1016/s0140-6736\(04\)15440-8](https://doi.org/10.1016/s0140-6736(04)15440-8).
96. Gasser P, Flammer J. Influence of vasospasm on visual function. *Doc Ophthalmol.* 1987;66(1):3–18. <https://doi.org/10.1007/bf00144735>.
97. Mustur D, Vahedian Z, Bovet J, et al. Retinal venous pressure measurements in patients with Flammer syndrome and metabolic syndrome. *EPMA J.* 2017;8(4): 339–344. <https://doi.org/10.1007/s13167-017-0105-7>.
98. Guthauser U, Flammer J, Mahler F. The relationship between digital and ocular vasospasm. *Graefes Arch Clin Exp Ophthalmol.* 1988;226(3):224–226. <https://doi.org/10.1007/bf02181185>.
99. Gramer G, Weber B, EJo Gramer, et al. Migraine and vasospasm in glaucoma: age-related evaluation of 2027 patients with glaucoma or ocular hypertension, 56(13): 7999–8007 <https://doi.org/10.1167/iov.15-17274>; 2015.
100. Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. *Am J Ophthalmol.* 2001;131(6): 699–708. [https://doi.org/10.1016/s0002-9394\(01\)00964-3](https://doi.org/10.1016/s0002-9394(01)00964-3).
101. Corbett JJ, Phelps CD, Eslinger P, et al. The neurologic evaluation of patients with low-tension glaucoma. *Invest Ophthalmol Vis Sci.* 1985;26(8):1101–1104.
102. Zahavi I, Chagnac A, Hering R, et al. Prevalence of Raynaud's phenomenon in patients with migraine. *Arch Intern Med.* 1984;144(4):742–744.
103. Hegyaljai T, Meienberg O, Dubler B, et al. Cold-induced acral vasospasm in migraine as assessed by nailfold video-microscopy: prevalence and response to migraine prophylaxis. *Angiology.* 1997;48(4):345–349. <https://doi.org/10.1177/000331979704800407>.
104. Flammer J, Pache M, Resnik T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. *Prog Retin Eye Res.* 2001;20(3):319–349. [https://doi.org/10.1016/s1350-9462\(00\)00028-8](https://doi.org/10.1016/s1350-9462(00)00028-8).
105. Gutteridge IF, McDonald RA, Plenderleith JG. Branch retinal artery occlusion during a migraine attack. *Clin Exp Optom.* 2007;90(5):371–375. <https://doi.org/10.1111/j.1444-0938.2007.00125.x>.
106. Dadaci Z, Doganay F, Oncel Acir N, et al. Enhanced depth imaging optical coherence tomography of the choroid in migraine patients: implications for the association of migraine and glaucoma. *Br J Ophthalmol.* 2014;98(7):972–975. <https://doi.org/10.1136/bjophthalmol-2013-304711>.
107. Choi J, Jeong J, Cho HS, et al. Effect of nocturnal blood pressure reduction on circadian fluctuation of mean ocular perfusion pressure: a risk factor for normal tension glaucoma. *Invest Ophthalmol Vis Sci.* 2006;47(3):831–836. <https://doi.org/10.1167/iov.05-1053>.
108. Choi J, Lee JR, Lee Y, et al. Relationship between 24-hour mean ocular perfusion pressure fluctuation and rate of paracentral visual field progression in normal-tension glaucoma. *Invest Ophthalmol Vis Sci.* 2013;54(9):6150–6157. <https://doi.org/10.1167/iov.13-12093>.
109. Tanito M, Kaidzu S, Takai Y, et al. Association between systemic oxidative stress and visual field damage in open-angle glaucoma. *Sci Rep.* 2016;6:25792. <https://doi.org/10.1038/srep25792>.
110. Yilmaz N, Coban DT, Bayindir A, et al. Higher serum lipids and oxidative stress in patients with normal tension glaucoma, but not pseudoexfoliative glaucoma. *Bosn J Basic Med Sci.* 2016;16(1):21–27. <https://doi.org/10.17305/bjbm.2016.830>.
111. Harada C, Noro T, Kimura A, et al. Suppression of oxidative stress as potential therapeutic approach for normal tension glaucoma. *Antioxidants.* 2020;9(9). <https://doi.org/10.3390/antiox9090874>.
112. Yuki K, Tsubota K. Increased urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG)/creatinine level is associated with the progression of normal-tension glaucoma. *Curr Eye Res.* 2013;38(9):983–988. <https://doi.org/10.3109/02713683.2013.800889>.
113. Himori N, Kunikata H, Shiga Y, et al. The association between systemic oxidative stress and ocular blood flow in patients with normal-tension glaucoma. *Graefes Arch Clin Exp Ophthalmol.* 2016;254(2):333–341. <https://doi.org/10.1007/s00417-015-3203-z>.
114. Mozaffarieh M, Schoetza A, Sauter M, et al. Comet assay analysis of single-stranded DNA breaks in circulating leukocytes of glaucoma patients. *Mol Vis.* 2008; 14:1584–1588.
115. Wunderlich K, Golubnitschaja O, Pache M, et al. Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study. *Mol Vis.* 2002;8:431–435.
116. Haefliger IO, Flammer J, Bény JL, et al. Endothelium-dependent vasoactive modulation in the ophthalmic circulation. *Prog Retin Eye Res.* 2001;20(2):209–225. [https://doi.org/10.1016/s1350-9462\(00\)00020-3](https://doi.org/10.1016/s1350-9462(00)00020-3).
117. Henry E, Newby DE, Webb DJ, et al. Altered endothelin-1 vasoreactivity in patients with untreated normal-pressure glaucoma. *Invest Ophthalmol Vis Sci.* 2006;47(6): 2528–2532. <https://doi.org/10.1167/iov.05-0240>.
118. Su WW, Cheng ST, Hsu TS, et al. Abnormal flow-mediated vasodilation in normal-tension glaucoma using a noninvasive determination for peripheral endothelial dysfunction. *Invest Ophthalmol Vis Sci.* 2006;47(8):3390–3394. <https://doi.org/10.1167/iov.06-0024>.
119. Buckley C, Hadoke PW, Henry E, et al. Systemic vascular endothelial cell dysfunction in normal pressure glaucoma. *Br J Ophthalmol.* 2002;86(2):227–232. <https://doi.org/10.1136/bjo.86.2.227>.
120. Cellini M, Strobb E, Gizzi C, et al. Endothelin-1 plasma levels and vascular endothelial dysfunction in primary open angle glaucoma. *Life Sci.* 2012;91(13-14): 699–702. <https://doi.org/10.1016/j.lfs.2012.02.013>.
121. Shoshani YZ, Harris A, Shojha MM, et al. Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. *Curr Eye Res.* 2012;37(1):1–11. <https://doi.org/10.3109/02713683.2011.622849>.
122. Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: players in the pathogenesis of glaucoma. *Mol Vis.* 2008;14:224–233.
123. Neufeld AH. Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. *Surv Ophthalmol.* 1999;43(Suppl 1):S129–S135. [https://doi.org/10.1016/s0039-6257\(99\)00010-7](https://doi.org/10.1016/s0039-6257(99)00010-7).
124. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. *Arch Ophthalmol.* 1997;115(4):497–503. <https://doi.org/10.1001/archophth.1997.01100150499009>.
125. Golubnitschaja O, Yeghiazaryan K, Liu R, et al. Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. *J Glaucoma.* 2004;13(1):66–72. <https://doi.org/10.1097/00061198-200402000-00013>.
126. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. *Am J Ophthalmol.* 1998; 126(4):487–497. [https://doi.org/10.1016/s0002-9394\(98\)00223-2](https://doi.org/10.1016/s0002-9394(98)00223-2).
127. Anderson DR. Normal-tension glaucoma (Low-tension glaucoma). *Indian J Ophthalmol.* 2011;59(Suppl1):S97–S101. <https://doi.org/10.4103/0301-4738.73695>. Suppl.
128. Gasser P, Flammer J. Short- and long-term effect of nifedipine on the visual field in patients with presumed vasospasm. *J Int Med Res.* 1990;18(4):334–339. <https://doi.org/10.1177/030006059001800411>.
129. Michalk F, Michelson G, Harazny J, et al. Single-dose nimodipine normalizes impaired retinal circulation in normal tension glaucoma. *J Glaucoma.* 2004;13(2): 158–162. <https://doi.org/10.1097/00061198-200404000-00013>.
130. Luksch A, Rainer G, Koyuncu D, et al. Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. *Br J Ophthalmol.* 2005;89(1):21–25. <https://doi.org/10.1136/bjo.2003.037671>.
131. Strenn K, Matulla B, Wolzt M, et al. Reversal of endothelin-1-induced ocular hemodynamic effects by low-dose nifedipine in humans. *Clin Pharmacol Ther.* 1998; 63(1):54–63. [https://doi.org/10.1016/s0009-9236\(98\)90121-7](https://doi.org/10.1016/s0009-9236(98)90121-7).
132. Adeghe J, Rahmatnejad K, Waisbourd M, et al. Intraocular pressure-independent management of normal tension glaucoma. *Surv Ophthalmol.* 2019;64(1):101–110. <https://doi.org/10.1016/j.survophthal.2018.08.005>.
133. Toriu N, Akaike A, Yasuyoshi H, et al. Lomerizine, a Ca²⁺ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. *Exp Eye Res.* 2000;70(4):475–484. <https://doi.org/10.1006/exer.1999.0809>.
134. Wilson RP, Chang WJ, Sergott RC, et al. A color Doppler analysis of nifedipine-induced posterior ocular blood flow changes in open-angle glaucoma. *J Glaucoma.* 1997;6(4):231–236.
135. Konieczka K, Flammer J. Treatment of glaucoma patients with flammer syndrome. *J Clin Med.* 2021;10(18). <https://doi.org/10.3390/jcm10184227>.
136. Song BJ, Caprioli J. New directions in the treatment of normal tension glaucoma. *Indian J Ophthalmol.* 2014;62(5):529–537. <https://doi.org/10.4103/0301-4738.133481>.
137. Yin B, Xu Y, Wei R, et al. Ginkgo biloba on focal cerebral ischemia: a systematic review and meta-analysis. *Am J Chin Med.* 2014;42(4):769–783. <https://doi.org/10.1142/s0192415x14500499>.
138. Chung SY, Cheng FC, Lee MS, et al. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. *Am J Chin Med.* 2006;34(5):803–817. <https://doi.org/10.1142/s0192415x06004302>.
139. Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma. *Mol Vis.* 2012;18: 390–402.
140. Park JW, Kwon HJ, Chung WS, et al. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. *Kor J Ophthalmol.* 2011;25(5):323–328. <https://doi.org/10.3341/kjo.2011.25.5.323>.
141. Catalgol B, Batirel S, Taga Y, et al. Resveratrol: French paradox revisited. *Front Pharmacol.* 2012;3:141. <https://doi.org/10.3389/fphar.2012.00141>.
142. Vahedian Z, Fakhraie G, Bovet J, et al. Nutritional recommendations for individuals with Flammer syndrome. *EPMA J.* 2017;8(2):187–195. <https://doi.org/10.1007/s13167-017-0093-7>.
143. Abu-Amro K, Kondkar A, Chalam KJN. Resveratrol and ophthalmic diseases. *Nutrients.* 2016;8(4):200. <https://doi.org/10.3390/nu8040200>.
144. Flammer J, Drance SM. Effect of acetazolamide on the differential threshold. *Arch Ophthalmol.* 1983;101(9):1378–1380. <https://doi.org/10.1001/archophth.1983.01040020380007>.
145. Terelak-Borys B, Grabska-Liberek I, Schoetza A, et al. Transient visual field impairment after cold provocation in glaucoma patients with Flammer syndrome. *Restor Neurol Neurosci.* 2019;37(1):31–39. <https://doi.org/10.3233/rmn-180866>.
146. Smith AD. Can we improve ocular blood flow and protect the eye? *hb TIMES Schw Aertzej.* 2021;(3):64–65. <https://doi.org/10.36000/hbT.2021.03.003>.
147. Thibaut Devogelaere AS. The effects of vitamin supplementation containing L-methylfolate (Ocufofolin® forte) on retinal venous pressure and homocysteine plasma levels in patients with glaucoma. *hb TIMES Schw Aertzej.* 2021;(3):54–59. <https://doi.org/10.36000/hbT.2021.03.001>.